Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

Switch Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for using Sifrol®, equivalent doses at the end of the switch and tolerability of Sifrol® in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions

Inclusion Criteria:

• Patients with Idiopathic Parkinson's disease who are planned to undergo a switch from another dopamine agonist to Sifrol®

Exclusion Criteria:

• Neurologists and psychiatrists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®